CSS
CYTK icon

Cubist Systematic Strategies’s Cytokinetics CYTK Stock Holding History

Cubist Systematic Strategies’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,400
Closed -$1.62M – 2979
2024
Q4 		$1.62M Sell
34,400
-9,700
-22% -$504K 0.01% 1507
2024
Q3 		$2.33M Sell
44,100
-3,200
-7% -$178K 0.01% 1342
2024
Q2 		$2.56M Buy
47,300
+3,200
+7% +$193K 0.02% 1172
2024
Q1 		$3.09M Buy
44,100
+39,900
+950% +$3.09M 0.02% 1311
2023
Q4 		$351K Buy
+4,200
New +$152K ﹤0.01% 2715

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cubist Systematic Strategies's CYTK Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 48,604 shares — an estimated $2.93M sold.

Cubist Systematic Strategies first reported a position in CYTK in Q1 2018 and held it in 18 quarters. The position peaked at $7.19M in Q4 2023. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 48,604 Cytokinetics shares in Q2 2024, an estimated $2.93M.
  • Cubist Systematic Strategies first reported a position in Cytokinetics in Q1 2018 and held it in 18 quarters.
  • Cubist Systematic Strategies's Cytokinetics position peaked at $7.19M in Q4 2023.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.